Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENTPD1 | P49961 | 3/20 | 0.77 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.70 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.69 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.66 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.66 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.66 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.66 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18858917 | 1.00 | ENTPD1 (0.77) | ENTPD1RNASELTRPM2P2RY1SRC | |
| SCHEMBL21283084 | 1.00 | ENTPD1 (0.77) | ENTPD1RNASELTRPM2P2RY1SRC | |
| SCHEMBL16805436 | 1.00 | ENTPD1 (0.77) | ENTPD1RNASELTRPM2P2RY1SRC | |
| SCHEMBL636535 | 0.92 | ENTPD1 (0.75) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL636536 | 0.92 | ENTPD1 (0.75) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL14945956 | 0.91 | SIRT2 (0.76) | ENTPD1RNASELTRPM2P2RY1SRC | |
| SCHEMBL15763588 | 0.91 | SIRT2 (0.76) | ENTPD1RNASELTRPM2P2RY1SRC | |
| SCHEMBL29398104 | 0.91 | ENTPD1 (0.74) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL374913 | 0.90 | ENTPD1 (0.73) | ENTPD1TRPM2P2RY1SRCP2RY2 | |
| SCHEMBL15082696 | 0.90 | ENTPD1 (0.73) | ENTPD1TRPM2P2RY1SRCP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | ENTPD1 251/4885RNASEL 35/4885TRPM2 4037/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | ENTPD1 251/4885RNASEL 35/4885TRPM2 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.